One of these is uPAR, associated with aggressive tumor features, invasion, and lymph node metastasis, which has been utilized in nanomedicine—targeted CRDA nanoparticles aimed at the uPAR receptor. This evidence concerns the gene PLAUR and metastatic malignant neoplasm in the lymph nodes.